SCHEDULE: Artelo Biosciences Stake Disclosed by Intracoastal Capital

Intracoastal Capital LLC, along with individuals Mitchell P. Kopin and Daniel B. Asher, have disclosed a beneficial ownership stake of 9.99% in Artelo Biosciences, Inc.

Summary

• Intracoastal Capital LLC, along with individuals Mitchell P. Kopin and Daniel B. Asher, have filed a Schedule 13G indicating beneficial ownership of 81,701 shares of Artelo Biosciences, Inc. common stock.
• This ownership stake represents approximately 9.99% of the company's outstanding common stock as of March 30, 2026.
• The reported shares include 81,000 shares of common stock and 701 shares issuable upon exercise of a warrant held by Intracoastal Capital LLC.
• The filing also notes blocker provisions on two warrants held by Intracoastal Capital LLC, which limit the exercise of these warrants to prevent beneficial ownership exceeding 9.99% and 4.99% respectively.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily reports on existing ownership and does not contain new financial performance data, strategic changes, or forward-looking guidance.

Positives

• Disclosure of a significant ownership stake (9.99%) by Intracoastal Capital LLC, Mitchell P. Kopin, and Daniel B. Asher, which could signal investor confidence or strategic interest in Artelo Biosciences.
• The reporting persons have certified that the securities were not acquired for the purpose of influencing control of the issuer.

Negatives

• The presence of blocker provisions on warrants indicates potential limitations on future share acquisition, suggesting a cautious approach or regulatory considerations.
• The filing does not provide details on the rationale behind acquiring this stake or future intentions beyond the certification of not influencing control.

Risks

• The blocker provisions on warrants limit the ability to exercise them, capping potential ownership and thus limiting upside from further warrant exercise.
• The filing does not provide forward-looking statements, leaving the future intentions and potential impact of this stake on the company's stock price uncertain.

Future Outlook

The filing does not contain any forward-looking statements or guidance from the company. The future outlook for Artelo Biosciences remains unaddressed by this specific filing.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors and significant individual investors acquiring a substantial stake in a public company. The 9.99% threshold is often a key reporting level, and the inclusion of blocker provisions suggests a strategic approach to managing ownership limits, possibly due to regulatory requirements or internal investment policies.

Stakeholder Impact

• Shareholders: The disclosure of a significant stake by Intracoastal Capital LLC may be interpreted as a positive signal by some investors, potentially influencing market perception. However, the blocker provisions suggest a capped interest, which might temper expectations of further aggressive acquisition.
• Management: The company's management will be aware of the significant ownership by these reporting persons, which could influence future strategic discussions or board composition considerations.
• Creditors: No direct impact on creditors is indicated by this filing.

Next Steps

• Monitor future filings from Intracoastal Capital LLC, Mitchell P. Kopin, and Daniel B. Asher for any changes in their beneficial ownership of Artelo Biosciences, Inc.
• Observe Artelo Biosciences, Inc.'s subsequent corporate actions and financial performance for potential impacts related to this disclosed stake.

Key Dates

Keywords

Schedule 13G, Artelo Biosciences, Intracoastal Capital LLC, Mitchell P. Kopin, Daniel B. Asher, Beneficial Ownership, Common Stock, Warrant, Blocker Provision, SEC Filing